Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label quadruple therapy study in genotype 1 chronic hepatitis C with compensated cirrhosis
2011-004150-26Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lomibuvir, telaprevir, interferon alfa and ribavirin in hepatitis C virus infection, sponsored by Vertex Pharmaceuticals. Primary endpoint: SVR12. Started Jan 2012; status: completed.
02
Drugs
lomibuvirtelaprevirinterferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-004150-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004150-26.